Business
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24. Presentation highlights include the ProstACT Global Phase
About this update from Telix Pharmaceuticals Limited
[{"type":"image","alt":"Telix Pharmaceuticals Limited","displaySize":"","headline":null,"caption":"Telix Pharmaceuticals Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":124,"url":"https://media.zenfs.com/en/globenewswire.com/6571dff84dd3c0b75b95cad39425eee7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KLoBa_N8Zvc1hCwyI8J_pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6571dff84dd3c0b75b95cad39425eee7","width":300,"height":124}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24.","length":442,"tagName":"p"},{"type":"text","content":"Presentation highlights include the ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer, preclinical data on Telix’s TLX252 alpha therapy candidate in CAIX1 -expressing tumors in combination with DDRIs2, and clinical study data on Illuccix® impact on decision-making.","length":283,"tagName":"p"},{"type":"text","content":"Two sponsored symposia will highlight innovation in precision diagnostics, the first on CAIX-PET3 imaging in renal cancer, and the second on Illuccix PSMA-PET4 imaging in prostate cancer, including Telix’s new PSMA biopsy trial.","length":228,"tagName":"p"},{"type":"text","content":"Dr. David N. Cade, Group Chief Medical Officer, Telix, said, “Telix’s broad representation at this year’s SNMMI Annual Meeting highlights the strength of our innovative pipeline and commercial programs. Our sponsored symposia, featuring leading key opinion leaders, further reflect our commitment to expanding clinical utility and advancing cancer care so that more patients may benefit from precision theranostics.”","length":416,"tagName":"p"},{"type":"text","content":"Visit booth #408 to discuss Telix’s extensive theranostic portfolio in urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), hematologic oncology, its investigational pan...